BioStem to Present at TD Cowen Healthcare Conference Amidst OTC Listing

Event summary

  • BioStem Technologies will present at the 46th Annual TD Cowen Healthcare Conference on March 2, 2026, in Boston.
  • The presentation will be accessible via webcast on the company’s investor relations website.
  • BioStem Technologies is an OTC-listed MedTech company focused on perinatal tissue-derived products.
  • The company utilizes a proprietary BioRetain® processing method and holds AATB accreditation for its quality management system.

The big picture

BioStem's presence at TD Cowen’s conference signals an effort to engage with a broader investor base, likely to bolster its OTC listing and raise awareness of its specialized approach to regenerative medicine. The company operates within a niche market focused on perinatal tissue, which presents both opportunities for differentiation and challenges related to sourcing and regulatory compliance. The conference presentation will be a key opportunity to articulate the value proposition of BioRetain® and address investor concerns about the company’s long-term viability.

What we're watching

Listing Status
The company's continued listing on the OTC market will be a key indicator of investor confidence and potential for future capital raises, particularly given the relatively small scale of the MedTech sector.
BioRetain® Adoption
The success of BioStem's proprietary BioRetain® processing method will dictate the company’s ability to differentiate its products and command premium pricing within the competitive regenerative therapies landscape.
Regulatory Scrutiny
Increased regulatory oversight of tissue banks and regenerative therapies, particularly concerning cGTP and cGMP compliance, could impact BioStem’s operational costs and product approval timelines.

Related topics

Regenerative Medicine